eligibility_summary
Consenting adults 18-75 with histologically/cytologically confirmed advanced/metastatic NSCLC not eligible for surgery/definitive chemoradiation, >=1 measurable lesion (RECIST v1.1), ECOG 0-1, adequate organ function. Exclude: untreated CNS/meningeal/spinal cord mets, uncontrolled effusions, other malignancy, active autoimmune disease, uncontrolled heart disease, ILD/pneumonitis, allergy to SHR-A1921/Adebrelimab/mAbs, prior topo I, TROP-2 ADC, ADC-topo I, or PD-1/PD-L1/CTLA-4 therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06434103 tests: 1) SHR-A1921: an antibody–drug conjugate (ADC). The registry does not name its target, but exclusions indicate a topoisomerase I inhibitor payload, MoA: binds a tumor surface antigen, is internalized, and releases a topo‑I inhibitor to induce DNA damage and tumor-cell death. 2) Adebrelimab: anti–PD‑L1 monoclonal antibody (immune checkpoint inhibitor), MoA: blocks PD‑L1 to restore T‑cell activity. 3) SHR‑8068: investigational immunotherapy, exact target/MoA not specified in the record. 4) Carboplatin: platinum chemotherapeutic, MoA: DNA crosslinking leading to apoptosis. Targets/pathways: tumor cells expressing the ADC’s antigen, PD‑1/PD‑L1 axis on T cells, DNA damage response/apoptosis pathways, plus the immune pathway modulated by SHR‑8068 (unspecified).